Beta Bionics, Inc. Common Stock
BBNXBeta Bionics, Inc. is a medical device company focused on developing innovative insulin delivery solutions for people with diabetes. It is known for its flagship product, the iLet Bionic Pancreas, an artificial pancreas system designed to automate insulin and glucagon delivery, aiming to improve glucose management and quality of life for users. The company emphasizes blending advanced technology with patient-centered design to address the needs of individuals requiring tight glucose control.
Company News
Shareholder rights law firm Robbins LLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) for potential securities law violations and breach of fiduciary duties. The investigation follows the company's January 8, 2026 announcement of fourth quarter 2025 results showing new patient starts of at least 5,581 (36% year-over-year growth), which fell ...
Robbins LLP is investigating Beta Bionics, Inc. for potential securities law violations and breach of fiduciary duties. The company reported Q4 2025 new patient starts of 5,581 (36% YoY growth), missing analyst expectations and showing a significant slowdown from the prior quarter's 68% growth. The stock declined over 35% following the January 9,...
The Portnoy Law Firm has initiated an investigation into possible securities fraud at Beta Bionics, Inc. and may file a class action lawsuit. The company's stock plummeted 37.03% on January 9, 2026, following disclosure of preliminary Q4 2025 results showing a significant slowdown in new user acquisition, with year-over-year growth declining from...
Pomerantz LLP is investigating potential securities fraud claims on behalf of investors in Beta Bionics, CVRx, and Navan. Beta Bionics experienced a significant stock price decline of 37% following the announcement of slower-than-expected patient growth in Q4 2025, with new patient starts increasing 36% year-over-year compared to 68% in the prior...
Securities law firm Faruqi & Faruqi is investigating Beta Bionics for potentially issuing misleading statements or failing to disclose material information to investors. The investigation was prompted by a 37% stock plunge on January 9, 2026, following the company's announcement of lower-than-expected patient starts in Q4.
